key: cord-0970167-wdgnddyf
authors: Khorshidi, Masoud; Zarezadeh, Meysam; Emami, Mohammadreza; Olang, Beheshteh; Moghaddam, Omid Moradi
title: Promising impacts of mesenchymal stem cell therapy in treatment of SARS-CoV-2 (COVID-19)
date: 2020-08-19
journal: Heart Lung
DOI: 10.1016/j.hrtlng.2020.08.007
sha: ed2cdcbfdb40a8ef9a4de2e17ed8936396fb5b08
doc_id: 970167
cord_uid: wdgnddyf

nan

A novel coronavirus named COVID-19 has begun to spread in Wuhan, China from December 2019 and become a global health concern [1] . Individuals with underlying diseases are at greater risk and more prone to be critically ill in case of infection so that mortality rate is 49% in subjects entering intensive care units [2] . It has been reported that critically ill COVID-19 patients remarkably have elevated levels of pro-inflammatory cytokines including IL-6, G-CSF, IP10, MCP1, MIP1A, and TNFα, contributing to outbreak of cytokine storm [3] . These turn of events lead to acute respiratory distress syndrome and ultimately maybe death [2] and glucocorticoids were not efficient in reducing rate of mortality [4] .

It has been suggested that mesenchymal stem cell (MSC) transplantation could be considered as a beneficial approach in treatment many disease. MSC exerts its positive impacts through immunomodulation and differentiation stimulation [5] . It has proposed that pathogen molecules such as double-stranded RNA in virus is able to increase induction of toll-like receptors (TLRs) on MSC resulting in manifestation of immunomodulatory effects of MSC [6] . Darwish et al. demonstrated that MSC is potentially able to treat H5N1 infection which has a cytokine profile similar to COVID-19 [7] . The mechanisms of action of MSC on COVID-19 treatment schematically are shown on Figure 1 .

Therefore, MSC therapy potentially could be considered as an efficacious and safe treatment approach in COVID-19-induced pneumonia. In this regard, Leng et al. recently demonstrated that with perfusion of 1 × 10 6 cells per kilogram of weight, almost all the clinical symptoms such as fever, breath shortness, and low oxygen saturation disappeared and the inflammation levels were relieved 2-4 days after MSC transplantation [8] . Moreover, in a critically ill 65 years old woman, MSC transplantation with 5×10 7 cells three times resulted in significant decrease in CRP and increase in CD3+, CD4+ and CD8+ T cells to the normal ranges. Also, CT images implied to remarkable relieve in pneumonia [9] . Furthermore, there are 30 registered studies investigating MSC therapy on COVID-19 to explore whether MSC transplantation could be able to shed the light in COVID-19 treatment. A summary of characteristics of registered studies are presented in Table 1 

Authors declare that there is no conflict of interest 

A novel coronavirus outbreak of global health concern

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome, American journal of respiratory and critical care medicine

Mesenchymal stem cells in health and disease

Mesenchymal stem cells: a double-edged sword in regulating immune responses

Immunomodulatory therapy for severe influenza

Transplantation of ACE2-Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia

Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells

All the registered studies are conducted on both genders MSC: mesenchymal stem cells; SCT: supportive and conventional treatment; NR: not reported; RCT: randomized controlled trial; IV: intravenous; CT: computed tomography; G: group; CTI: critical treatment index; TTCI: time to clinical improvement; pro-BNP: pro-type B natriuretic peptide; ALT: alanine aminotransferase.